Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Current Assets (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Current Assets for 6 consecutive years, with $157.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 46.29% to $157.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $157.2 million, a 46.29% decrease, with the full-year FY2025 number at $157.2 million, down 46.29% from a year prior.
  • Current Assets was $157.2 million for Q4 2025 at TScan Therapeutics, down from $188.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $299.5 million in Q2 2024 to a low of $100.9 million in Q1 2023.
  • A 5-year average of $190.0 million and a median of $187.0 million in 2021 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 354.53% in 2021, then plummeted 46.29% in 2025.
  • TScan Therapeutics' Current Assets stood at $165.7 million in 2021, then dropped by 25.07% to $124.1 million in 2022, then surged by 56.48% to $194.2 million in 2023, then soared by 50.7% to $292.7 million in 2024, then tumbled by 46.29% to $157.2 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Current Assets are $157.2 million (Q4 2025), $188.2 million (Q3 2025), and $221.1 million (Q2 2025).